EMEA pharmaceutical news in briefs.
* EMEA has also released a draft policy on obtaining practical access to its documents--http://www.emea.europa.eu/pdfs/general/direct/11019606en.pdf;
* This includes a document on accessing its adverse reactions database EudraVigilance--http://www.emea.europa.eu/ pdfs/human/phv/18743906en.pdf.
Other recent EMEA documents include a guideline on the clinical development of medicinal products for the treatment of HIV infection
(http://www.emea.europa.eu/pdfs/human/ewp/63302enfin.pdf); and developing specific immunotherapy products treating allergic diseases
|Printer friendly Cite/link Email Feedback|
|Publication:||International News Services.com|
|Date:||Jan 1, 2009|
|Previous Article:||EU researchers use nanoparticles to help drugs target tumuors.|
|Next Article:||Anti-money laundering is become a profession, but a universal model is a far away.|